Skip to main content

Semaglutide Insights: Assessing Benefits & Improvement on Side Effects

 Semaglutide: From Hypoglycemic Drug to Beauty Trend

This year, semaglutide has gained widespread popularity, but not solely for its intended use as a hypoglycemic drug. Instead, it's being embraced for its remarkable weight loss effects, transforming it into a "beauty drug" and creating a market frenzy. This shift has led to concerns about its availability for those who need it most—diabetics.

Semaglutide's Primary Function: Blood Sugar Control
Semaglutide is a natural GLP-1 analog that, when introduced into the body, impacts pancreatic islet B cells. It enhances the responsiveness of these cells to glucose, promoting normalized glucose metabolism and ultimately lowering blood sugar levels. Its primary indication remains blood sugar control, as outlined in its instruction manual, with weight loss benefits not being the main focus.

The Weight Loss Hype
Despite its primary use, many have turned to semaglutide for its significant weight loss effects. Users have reported substantial results, with some losing up to 5 pounds in just two weeks and others seeing even more dramatic changes. This has led to semaglutide being dubbed the "beauty needle" and achieving "net red medicine" status.

FDA Approval and Clinical Results
In December 2014, the FDA approved liraglutide for weight loss, showing promising results in clinical trials. By 2023, semaglutide, a more effective alternative, received FDA approval for long-term weight control in overweight or obese patients. Studies indicate that most people treated with 2.4 mg of semaglutide lose more than 10% of their body weight, supporting the idea that obesity can be managed as a chronic disease. In China, the SUSTAIN study showed that semaglutide at doses of 0.5 mg and 1 mg resulted in weight reductions of 3.1 kg and 4.0 kg, respectively.

Advancements in Semaglutide: Injection vs. Oral Version
Initially listed abroad at the end of 2017, semaglutide became available in China on April 27, 2023, and was added to the local medical insurance negotiation catalog on December 3, 2023. On March 24, 2023, Novo Nordisk announced phase III clinical data for the oral version of semaglutide. The study showed that daily oral doses of 14mg, 25mg, and 50mg resulted in weight reductions of 4.4 kg, 6.7 kg, and 8.0 kg, respectively, after one year.

Ease of Use: Injection vs. Oral Semaglutide
The oral version of semaglutide is more convenient compared to injections. Oral medications are easier to store and carry, making them more appealing to many users. Both forms share similar safety profiles, with gastrointestinal reactions being the most common adverse effects. Mild to moderate nausea is typical but tends to decrease over time. In terms of effectiveness, both the injection and oral versions of semaglutide are equally potent.

Using BD Pen Needles for Semaglutide Administration
When administering semaglutide via injection, the BD pen needles are a crucial accessory. BD pen needles are designed for comfort and ease of use, ensuring precise and efficient medication delivery. They are compatible with semaglutide pens, enhancing the overall experience for users who prefer injections over oral medication.

Semaglutide's transition from a hypoglycemic drug to a weight loss sensation highlights its versatility. While it offers significant benefits for blood sugar control and weight loss, it's essential to use it under medical guidance. The availability of both injection and oral versions provides flexibility in administration methods, with tools like BD pen needles ensuring smooth and effective injections. Medication is just one part of a comprehensive approach to weight loss, which should include a balanced diet and regular exercise for optimal results.

Comments

Post a Comment

Popular posts from this blog

Blood Sugar Lowering Exercises: Are You on Track?

  Exercise to lower blood sugar, you may have been doing it wrong Research results show that in men with type 2  diabetes , high-intensity interval training in the afternoon appeared to be better at improving blood sugar levels than exercising in the morning during the first two weeks of a training regimen. And when you exercise in the morning, your blood sugar control is slightly worse. This study data highlights the importance of optimizing exercise timing to improve glycemic control in type 2 diabetes. Therefore, people with diabetes should choose scientific and reasonable exercise and avoid the following "seven unsuitable" exercises to lower blood sugar. 1. It is not advisable to exercise when the following conditions occur: 1. Blood sugar >16.7 mmol/L or fluctuates greatly: 2. Acute complications of diabetes such as acute infection; 3. Severe diabetic nephropathy; 4. Retinopathy with fundus hemorrhage; 5. Diabetic foot; 6. Serious cardiovascular and cerebrovascular di...
Post a Comment
Read more

Diabetes in Seniors: 4 Crucial Management Differences

  The elderly are the main force among the diabetic population. When the house leaks and it rains all night long, elderly people with   diabetes   often suffer from diseases such as high blood pressure, dyslipidemia, coronary heart disease, and cerebral infarction. The body's metabolic capacity also deteriorates, and their eyesight and legs and feet are also less flexible. Therefore, in the view of our doctors, elderly people with diabetes are the key targets of protection and must be closely monitored. On the road to fighting against the devil, they are different from ordinary adult diabetic patients. One of the differences - eating: no need to deliberately lose weight Many elderly people with diabetes believe that they are too fat and their blood sugar is too high because of food, so they control their diet extremely harshly, causing their bodies to lose weight day by day. At this time, they are secretly happy, after all, "it is hard to buy old age to lose weight." ! Ye...
Post a Comment
Read more

Revolutionizing Therapy: Panacea's Next Leap - Unveiling the Future of Injection Pens

  Do you still have a sense of boundaries? I’m talking about semaglutide. On October 10, Novo Nordisk announced that the Phase III clinical trial of semaglutide in the treatment of kidney damage patients with type 2 diabetes and chronic kidney disease was terminated early due to excellent efficacy. GLP-1 drugs are becoming a panacea, from reducing blood sugar and weight to chronic kidney disease, NASH, Alzheimer's disease, Parkinson's disease, obstructive sleep apnea, intermittent claudication, dyslipidemia, and even improving psoriasis disease symptoms. In May this year, "Frontiers in Pharmacology" also discussed the treatment of GLP-1 for inflammatory bowel disease (IBD), mucositis, short bowel syndrome, acute lung injury, pulmonary fibrosis, and pulmonary hypertension. Who can withstand this? The GLP-1 industry chain has finally become fragrant and long, from downstream drugs (Innovent Biologics, Hengrui Pharmaceuticals, Huadong Medicine, Changshan Pharmaceuticals,...
Post a Comment
Read more